All Oncology News

Vincent Ma, MD, emphasizes the need for novel therapies for patients with melanoma who are refractory to or ineligible for standard checkpoint inhibition.

SVR10 at week 12 was associated with favorable OS among patients with myelofibrosis and thrombocytopenia treated with pacritinib in the PERSIST-2 trial.

In a study recently published by researchers at Fox Chase Cancer Center, patients being treated for retroperitoneal sarcoma at multiple facilities experienced longer delays between diagnosis and treatment.

Talquetamab plus teclistamab produced responses with a high rate of infections in relapsed/refractory multiple myeloma.

Zanubrutinib showed high response rates and durable responses among Japanese patients with CLL/SLL and Waldenström macroglobulinemia.

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

FDA’s ODAC voted on therapeutic approaches in lymphoma, bladder, prostate, and myeloma, and more from OncLive this week.

Momelotinib was associated with anemia benefits and reduced transfusion burden in myelofibrosis in a post hoc analysis of 4 trials.

Alana Welm, PhD, is now the chair of the Department of Oncological Sciences in the Spencer Fox Eccles School of Medicine at the University of Utah.

The EMA’s CHMP has recommended the approval of inavolisib plus palbociclib/fulvestrant in PIK3CA-mutated, ER-positive advanced breast cancer.

The EMA’s CHMP has recommended the approval of obecabtagene autoleucel for adult patients with relapsed/refractory B-ALL.

Two-year follow-up data continued to show an overall survival benefit with glofitamab plus chemotherapy in relapsed/refractory DLBCL.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of belantamab mafodotin (Blenrep) in adult patients with relapsed or refractory multiple myeloma.

The EMA’s CHMP has issued a positive opinion for mirdametinib for pediatric and adult patients with NF1-associated plexiform neurofibromas.

Seema A. Bhat, MD, discusses the current treatment landscape of chronic lymphocytic leukemia in light of the FDA approvals of liso-cel and pirtobrutinib.

Barriers in utilizing remote collection of patient-reported outcomes persist, although it has been proven to be effective in breast cancer.

GI cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Inavolisib plus palbociclib and fulvestrant improved OS in PIK3CA-mutant, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer.

IMforte data highlight potential for lurbinectedin plus atezolizumab to become a new SOC for first-line maintenance treatment in ES-SCLC.

AI-assisted training of pathologists enhanced the accuracy of HER2 IHC scoring, potentially expanding eligibility for HER2-targeted treatments.

The use of GLP-1 agonists was not associated with higher cancer rates and led to a decrease in obesity-related cancers in adults with diabetes.

Olutasidenib was effective both as monotherapy and in combination with azacitidine in patients with IDH1-mutated AML arising from an MPN.

Multiple experts on artificial intelligence in cancer care discuss its ever-expanding role in several areas of oncology.

CPRIT awards over $21 million to MD Anderson for cancer research and faculty recruitment.

Osimertinib, with conditions, has been approved by Health Canada for locally advanced, unresectable NSCLC, harboring EGFR mutations.

The FDA granted breakthrough device designation to EnVisio X1 for minimally invasive surgery in cancer care.

There remains a significant unmet need for better treatments that prolong life and preserve the quality of life in women with metastatic breast cancer.

A post hoc analysis from the APHINITY trial showed statin use did not improve survival in early-stage HER2-positive breast cancer.

Ahead of the 2025 ASCO Annual Meeting, experts in genitourinary cancers share the most anticipated research being presented during the meeting.

The FDA’s ODAC voted 8 to 0 against the risk/benefit profile of talazoparib in combination with enzalutamide for patients with non-HRR–mutant mCRPC.